Kadcyla® (ado-trastuzumab emtansine) – New indication
May 3, 2019 - Genentech announced the FDA approval of Kadcyla (ado-trastuzumab emtansine), as a single agent, for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and Herceptin® (trastuzumab)-based treatment.
Top